Innate Pharma strengthens international management team by appointing Director of Business Development
Agustín de la Calle brings international business development experience acquired in Germany and the USA

Marseilles, June 12, 2005 - Innate Pharma, developer of novel anti-tumoral therapies, announces today the appointment of Agustín de la Calle to head business development. Dr. de la Calle's will be primarily responsible for initiating and maintaining partnerships with the pharma industry, while increasing the company's international presence. The appointment comes as Innate Pharma is building up a significant portfolio of drug candidates and industry partnerships.

Agustín de la Calle, Ph.D., 41, comes to Innate Pharma after serving since 2002 as Director of business development at antibody-based drug discovery company, Micromet AG in Germany. Previously he was with Eos Biotechnology, Inc., USA, (now part of Protein Design Labs, Inc.), where he joined as a scientist in 2000. Earlier in his career, Dr. de la Calle served as Manager of business development at Exelixis, Inc., USA and as a consultant to several pharmaceutical and biotechnology companies during his work for The Mendel Group. He received his M.S. from the Free University of Berlin, Germany; his Ph.D. was awarded from the Free University of Berlin after he carried out his research at Harvard Medical School. He conducted his postdoctoral studies at M.I.T.

"The appointment of Agustín de la Calle is an important step in Innate's strategy to become a global leader in the field of novel immunomodulators", said Hervé Brailly, CEO of Innate Pharma. "Agustín's international business experience and skills in dealing successfully with pharmaceutical and biotech companies complement Innate Pharma's scientific and management expertise and have already shown their value in promoting international partnerships."

About Innate Pharma: www.innate-pharma.com
Innate Pharma S.A.S., is a French biopharmaceutical company in clinical development stage specialized in cancer immuno-therapeutics. It is the first company to develop immunomodulating agents targeting non-conventional lymphocytes. The company has currently two products in Phase I of clinical development in cancer. The company was founded in 1999, and has raised EUR40 million in private funding since inception in three rounds of financing.
Companies investing in Innate are Novo-Nordisk (Copenhagen), NIF (Tokyo), Quilvest (Paris), Sofinnova Partners (Paris), Alta Partners (San Francisco), GIMV (Anvers), Auriga Partners (Paris), Axa Private Equity (Paris), Gilde Biotech & Nutrition (Utrecht), Pechel Industries (Paris), Innoveris (Marseille) and Inserm-Transfert (Paris).

Innate Pharma has 47 employees as of June 2005.

For further information please contact:

Andrew Lloyd & Associates
Gilles Petitot / Heidi Thompson
Phone: +44 1273 675100
gilles@ala.com  / heidi@ala.com